Amneal Pharmaceuticals, Inc. $AMRX Stock: Pictet Asset Management Holding SA Grows Holdings

Pictet Asset Management Holding SA boosted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 4.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 638,040 shares of the company’s stock after buying an additional 26,810 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Amneal Pharmaceuticals were worth $12,887,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of AMRX. Paralel Advisors LLC purchased a new stake in Amneal Pharmaceuticals during the 2nd quarter worth approximately $3,217,000. California State Teachers Retirement System lifted its position in shares of Amneal Pharmaceuticals by 37.6% in the first quarter. California State Teachers Retirement System now owns 207,239 shares of the company’s stock valued at $2,576,000 after acquiring an additional 56,588 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Amneal Pharmaceuticals by 1,586.8% in the first quarter. Renaissance Technologies LLC now owns 276,637 shares of the company’s stock valued at $3,439,000 after acquiring an additional 260,237 shares in the last quarter. Congress Asset Management Co. boosted its stake in shares of Amneal Pharmaceuticals by 94.7% in the third quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company’s stock worth $30,701,000 after acquiring an additional 741,577 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in shares of Amneal Pharmaceuticals by 26.3% in the first quarter. Sei Investments Co. now owns 706,681 shares of the company’s stock worth $8,784,000 after acquiring an additional 147,249 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Stock Down 0.0%

Shares of NASDAQ AMRX opened at $21.70 on Friday. The stock has a market cap of $6.93 billion, a PE ratio of 22.85, a P/E/G ratio of 2.47 and a beta of 1.24. The company has a current ratio of 1.87, a quick ratio of 1.24 and a debt-to-equity ratio of 5.61. Amneal Pharmaceuticals, Inc. has a 12-month low of $11.39 and a 12-month high of $22.07. The company has a 50-day moving average of $19.64 and a 200 day moving average of $16.07.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.03. The business had revenue of $862.68 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.17% and a return on equity of 283.50%. As a group, sell-side analysts predict that Amneal Pharmaceuticals, Inc. will post 0.98 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on AMRX. The Goldman Sachs Group reiterated a “buy” rating and set a $24.00 price target on shares of Amneal Pharmaceuticals in a research report on Thursday, October 29th. Piper Sandler reissued an “overweight” rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a research note on Wednesday, November 4th. Oppenheimer started coverage on Amneal Pharmaceuticals in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $27.00 price objective on the stock. Barclays lifted their target price on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, September 17th. Finally, JPMorgan Chase & Co. upped their target price on shares of Amneal Pharmaceuticals from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, November 4th. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $23.00.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.